Prime Medicine Inc
PRME
NASDAQ
Biotechnology
$3.09
USD
-0.08 (-2.52%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $574.96M
Volume 1.6M
Revenue
$4.07M
TTM
-17.9%
YoY
Gross Margin
100%
TTM
0.0%
YoY
Net Income
$-187.89M
TTM
+5.7%
YoY
Operating Cash Flow
$-156.05M
TTM
-56.2%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Revenue | 1.1 | 1.2 | 0.8 | 0.9 | 1.2 |
YoY Growth | — | +486.1% | -61.6% | -41.1% | +3.5% |
Cost of Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross Profit | 1.1 | 1.2 | 0.8 | 0.9 | 1.2 |
Selling, General & Administrative | 13.1 | 11.2 | 14.7 | 17.4 | 11.0 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Operating Expenses | 54.5 | 55.2 | 49.4 | 51.5 | 44.4 |
Operating Income | -53.4 | -54.0 | -48.6 | -50.7 | -43.3 |
EBITDA | -51.5 | -52.1 | -46.7 | -48.8 | -41.5 |
Other Income / Expense | 0.0 | 2.3 | 1.4 | 0.5 | 0.4 |
Total Other Income / Expense | 0.8 | 3.4 | 2.5 | 1.5 | 1.2 |
Income Before Income Taxes | -52.6 | -50.6 | -46.1 | -49.1 | -42.1 |
Income Taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Net Income | -52.6 | -50.6 | -46.1 | -49.1 | -42.1 |
Consolidated Net Income / Loss | -52.6 | -50.6 | -46.1 | -49.1 | -42.1 |
Net Income Attributable to Common Shareholders | -52.6 | -50.6 | -46.1 | -49.1 | -42.1 |
Basic EPS | -$0.41 | -$0.32 | -$0.26 | -$0.28 | -$0.24 |
Diluted EPS | -$0.41 | -$0.32 | -$0.26 | -$0.28 | -$0.24 |
Basic Shares Outstanding | 129.2M | 160.5M | 174.5M | 177.1M | 177.2M |
Diluted Shares Outstanding | 129.2M | 160.5M | 174.5M | 177.1M | 177.2M |